Paolino, D. published the artcilePolyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer brugs, Quality Control of 6249-56-5, the publication is Biomacromolecules (2008), 9(4), 1117-1130, database is CAplus and MEDLINE.
In this paper we report on three different hydrophilic copolymers based on α,β-polyaspartylhydrazide (PAHy) bearing butyric groups in the side chain (C4) (PAHy-C4) or a combination of butyric groups and pos. charged residues ((carboxypropyl)trimethylammonium chloride, CPTACl) (PAHy-C4-CPTA) that were synthesized and used for the preparation of new supramol. vesicular aggregates (SVAs) containing gemcitabine as an antitumor drug. Gemcitabine-loaded SVAs containing synthesized PAHy derivatives were characterized from the physicochem. and technol. point of view and the in vitro toxicity and anticancer activity on two different human cancer cell lines, i.e., CaCo-2 (human colon carcinoma) and ARO (human anaplastic thyroid carcinoma) cells, were also evaluated. Moreover, considering that carrier-cell interaction is an important factor to achieve an improvement of anticancer drug activity, confocal laser scanning microscopy and flow cytometric experiments were carried out on the two different cancer cell lines.
Biomacromolecules published new progress about 6249-56-5. 6249-56-5 belongs to chlorides-buliding-blocks, auxiliary class Phase Transfer Catalyst,Inhibitor,Natural product, name is 3-Carboxy-N,N,N-trimethylpropan-1-aminium chloride, and the molecular formula is C7H16ClNO2, Quality Control of 6249-56-5.
Referemce:
https://en.wikipedia.org/wiki/Chloride,
Chlorides – an overview | ScienceDirect Topics